Emopamil: Difference between revisions
CSV import |
CSV import |
||
| Line 24: | Line 24: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
== Emopamil gallery == | |||
<gallery> | |||
File:emopamil.png|Emopamil | |||
</gallery> | |||
Revision as of 05:14, 3 March 2025
Emopamil is a calcium channel blocker and sigma receptor ligand that has been studied for its potential use in the treatment of cardiovascular disease.
Pharmacology
Emopamil acts as a calcium channel blocker, inhibiting the influx of calcium ions into cardiac and smooth muscle cells. This action can lead to a decrease in blood pressure and a reduction in heart rate. Emopamil also has affinity for sigma receptors, which are thought to be involved in various physiological processes, including the regulation of neurotransmitter release.
Clinical Use
While emopamil has been studied for its potential use in the treatment of cardiovascular disease, it has not been approved for this use by any regulatory authority. The drug's effects on the cardiovascular system, including its ability to lower blood pressure and reduce heart rate, could potentially make it useful in the treatment of conditions such as hypertension and angina pectoris.
Side Effects
As with other calcium channel blockers, potential side effects of emopamil could include dizziness, headache, flushing, and edema. Due to its sigma receptor activity, emopamil could also potentially cause neurological side effects.
